Skip to main content
Premium Trial:

Request an Annual Quote

GeneBio Signs On Hitachi as Direct Distributor for Mass Spec Protein ID Software in Japan

NEW YORK, June 2 (GenomeWeb News) - Geneva Bioinformatics has signed on Hitachi Software Engineering as a direct distribution partner for its mass spectrometry protein identification software in Japan, the company said today.

 

Under the agreement, Hitachiwill sell GeneBio's Phenyx software in Japan, in collaboration with GeneBio's Japanese branch.

 

Hitachihas already been selling Phenyx in Japansince November, when GeneBio signed a distribution deal with the Bioinformatics Institute for Global Good, which has business relationships with Hitachiand a number of other companies as well as acadmic institutions.

 

Now, GeneBio will deal directly with Hitachi, which will receive a higher commission for sales of Phenyx, GeneBio marketing manager Andrew Smith told GenomeWeb News today. GeneBio will retain its relationship with BiGG for sales through other channels.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.